Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Other Accumulated Expenses (2023 - 2025)

Immunome's Other Accumulated Expenses history spans 3 years, with the latest figure at $3.6 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 54.55% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $3.6 million, down 54.55%, while the annual FY2025 figure was $3.6 million, 54.55% down from the prior year.
  • Other Accumulated Expenses reached $3.6 million in Q4 2025 per IMNM's latest filing, down from $15.6 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $15.6 million in Q3 2025 to a low of $489000.0 in Q2 2023.
  • Average Other Accumulated Expenses over 3 years is $6.3 million, with a median of $5.0 million recorded in 2024.
  • Peak YoY movement for Other Accumulated Expenses: soared 2856.65% in 2024, then crashed 54.55% in 2025.
  • A 3-year view of Other Accumulated Expenses shows it stood at $732000.0 in 2023, then soared by 989.89% to $8.0 million in 2024, then plummeted by 54.55% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Other Accumulated Expenses are $3.6 million (Q4 2025), $15.6 million (Q3 2025), and $10.6 million (Q2 2025).